Alkermes PLC
ALKS—
Build a strategy around ALKS
Alkermes PLC AI Insights
Informational only. Not investment advice.Snapshot
- ROE of 22.4% TTM vs industry median of -38% - profitable outlier in loss-making biotech sector[Return on Equity]
- FCF of 491M TTM (32% margin) with only 72M total debt - self-funding growth with 0.04 debt/equity[Free Cash Flow]
- Operating margin 23.6% TTM vs industry median of 0% - rare profitability in R&D-heavy pharma[Operating Margin]
Watch Triggers
- Operating Margin: Falls below 20% TTM — Would signal pricing pressure or R&D cost inflation eroding core advantage
- Free Cash Flow: Drops below 400M TTM — Indicates deteriorating conversion or increased capex needs
- R&D Expense: Exceeds 25% of revenue — May signal pipeline issues requiring accelerated investment
Bull Case
Exceptional capital efficiency: ROIC 19.6% TTM with near-zero leverage (0.04 D/E) in an industry where median company loses money
ROICDebt to EquityROE
FCF conversion of 91% (491M FCF vs 541M operating CF TTM) with capex under 4% of revenue enables buybacks or M&A
Free Cash FlowCapital ExpenditureCash Flow
Bear Case
P/E of 16.4x near industry median (20.3x) despite superior margins - limited multiple expansion potential
P/E RatioP/S Ratio
Revenue of 1.5B TTM concentrated in specialty pharma - single product risk not visible in aggregates
Total RevenueGross Margin
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
62%
Leverage ALKS's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Cash generation to accelerate as R&D (19% of revenue) yields pipeline optionality
1-3ymed
- 491M FCF TTM funds internal R&D without dilution
- 616M cash provides M&A flexibility
- Minimal debt (72M) preserves balance sheet
R&D 289M TTM vs 491M FCF - fully fundedWorking capital 1.3B provides cushionROIC 19.6% TTM shows capital efficiency
Valuation Context
Caveats
Public Strategies Rankings
See how Alkermes PLC ranks across different investment strategies.
Leverage ALKS's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
ALKS Fundamentals
Manufacturing → Chemical Manufacturing
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$5.6B | — | ||
$5.28B | — | ||
23 | — | ||
$1.48B | -5.2% | — | |
$1.43 | -35.0% | — | |
17.2% | -9.8% | — | |
16.4% | -7.2% | — | |
$480.33M | +18.4% | — | |
14.7% | -12.8% | — | |
Beta 5Y (Monthly) | unknown | — |
ALKS Dividend History
No dividends
ALKS Stock Splits
1 stock split
05/15/000.5:1 split
ALKS SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
02/25/26 | 12/31/25 | Unknown | |
10/28/25 | 09/30/25 | 10-Q | |
07/29/25 | 06/30/25 | 10-Q | |
05/01/25 | 03/31/25 | 10-Q | |
02/12/25 | 12/31/24 | 10-K | |
10/24/24 | 09/30/24 | 10-Q | |
07/24/24 | 06/30/24 | 10-Q | |
05/01/24 | 03/31/24 | 10-Q | |
02/21/24 | 12/31/23 | 10-K | |
10/25/23 | 09/30/23 | 10-Q | |
07/26/23 | 06/30/23 | 10-Q | |
04/26/23 | 03/31/23 | 10-Q | |
02/16/23 | 12/31/22 | 10-K | |
11/02/22 | 09/30/22 | 10-Q | |
07/27/22 | 06/30/22 | 10-Q | |
04/27/22 | 03/31/22 | 10-Q | |
02/16/22 | 12/31/21 | 10-K | |
10/27/21 | 09/30/21 | 10-Q | |
07/28/21 | 06/30/21 | 10-Q | |
04/28/21 | 03/31/21 | 10-Q | |
02/11/21 | 12/31/20 | 10-K | |
10/29/20 | 09/30/20 | 10-Q | |
07/29/20 | 06/30/20 | 10-Q | |
04/29/20 | 03/31/20 | 10-Q | |
02/13/20 | 12/31/19 | 10-K | |
10/23/19 | 09/30/19 | 10-Q | |
07/25/19 | 06/30/19 | 10-Q | |
04/25/19 | 03/31/19 | 10-Q | |
02/15/19 | 12/31/18 | 10-K | |
10/23/18 | 09/30/18 | 10-Q | |
07/26/18 | 06/30/18 | 10-Q | |
04/26/18 | 03/31/18 | 10-Q | |
02/16/18 | 12/31/17 | 10-K | |
10/26/17 | 09/30/17 | 10-Q | |
07/27/17 | 06/30/17 | 10-Q | |
04/27/17 | 03/31/17 | 10-Q | |
02/17/17 | 12/31/16 | 10-K | |
11/02/16 | 09/30/16 | 10-Q | |
07/28/16 | 06/30/16 | 10-Q | |
04/28/16 | 03/31/16 | 10-Q | |
02/25/16 | 12/31/15 | 10-K | |
10/29/15 | 09/30/15 | 10-Q | |
07/30/15 | 06/30/15 | 10-Q | |
04/30/15 | 03/31/15 | 10-Q | |
02/24/15 | 12/31/14 | 10-K | |
10/29/14 | 09/30/14 | 10-Q | |
07/31/14 | 06/30/14 | 10-Q | |
04/30/14 | 03/31/14 | 10-Q | |
10/31/13 | 09/30/13 | 10-Q | |
07/25/13 | 06/30/13 | 10-Q | |
05/23/13 | 03/31/13 | 10-K | |
01/31/13 | 12/31/12 | 10-Q | |
11/01/12 | 09/30/12 | 10-Q | |
07/26/12 | 06/30/12 | 10-Q | |
05/18/12 | 03/31/12 | 10-K | |
02/02/12 | 12/31/11 | 10-Q | |
11/03/11 | 09/30/11 | 10-Q | |
08/01/11 | 06/30/11 | 10-Q | |
05/20/11 | 03/31/11 | 10-K | |
02/03/11 | 12/31/10 | 10-Q | |
11/04/10 | 09/30/10 | 10-Q | |
08/06/10 | 06/30/10 | 10-Q | |
05/21/10 | 03/31/10 | 10-K | |
02/04/10 | 12/31/09 | 10-Q | |
11/05/09 | 09/30/09 | 10-Q | |
08/06/09 | 06/30/09 | 10-Q | |
05/28/09 | 03/30/09 | 10-K | |
12/31/08 | 12/31/08 | Unknown | -- |
09/30/08 | 09/30/08 | Unknown | -- |
06/30/08 | 06/30/08 | Unknown | -- |
03/31/08 | 03/30/08 | Unknown | -- |
12/31/07 | 12/31/07 | Unknown | -- |
09/30/07 | 09/30/07 | Unknown | -- |
06/30/07 | 06/30/07 | Unknown | -- |
03/31/07 | 03/30/07 | Unknown | -- |
12/31/06 | 12/31/06 | Unknown | -- |
09/30/06 | 09/30/06 | Unknown | -- |
06/30/06 | 06/30/06 | Unknown | -- |
03/31/06 | 03/30/06 | Unknown | -- |
12/31/05 | 12/31/05 | Unknown | -- |
09/30/05 | 09/30/05 | Unknown | -- |
06/30/05 | 06/30/05 | Unknown | -- |
03/31/05 | 03/30/05 | Unknown | -- |
12/31/04 | 12/31/04 | Unknown | -- |
09/30/04 | 09/30/04 | Unknown | -- |
06/30/04 | 06/30/04 | Unknown | -- |
03/31/04 | 03/30/04 | Unknown | -- |
12/31/03 | 12/31/03 | Unknown | -- |
09/30/03 | 09/30/03 | Unknown | -- |
06/30/03 | 06/30/03 | Unknown | -- |
03/31/03 | 03/30/03 | Unknown | -- |
12/31/02 | 12/31/02 | Unknown | -- |
09/30/02 | 09/30/02 | Unknown | -- |
06/30/02 | 06/30/02 | Unknown | -- |
03/31/02 | 03/30/02 | Unknown | -- |
12/31/01 | 12/31/01 | Unknown | -- |
09/30/01 | 09/30/01 | Unknown | -- |
06/30/01 | 06/30/01 | Unknown | -- |
03/31/01 | 03/30/01 | Unknown | -- |
12/31/00 | 12/31/00 | Unknown | -- |
09/30/00 | 09/30/00 | Unknown | -- |
06/30/00 | 06/30/00 | Unknown | -- |
03/31/00 | 03/30/00 | Unknown | -- |